Have you a Share with an interesting Trend or TA?
Looking around the various threads and especially Max up your Sip ISA and PEPs thread on Traders Room, I think it may be of interest to see what others have on their watch list or in their portfolios. Ie. Pondering over buying or selling.

Intimating reasons for buying or holding. I was thinking of addressing the thread to longer term trading ie anything over 3mins up to 5years.

If there is interest it may be reasonable to cut and paste some to the postings to a thread under the epic name for further follow up or discussion.

I will kick off with one of my failures, which I should have cut my losses on. But to a certain degree is still a free ride as I sold at the peak to buy again later. (If there is such a thing, and if there is why is it sometimes so bloody painful.)

Amstrad.







Bought originally because of :-

1) Promising rolling yield about 4.8%
2) Dividend cover of about 3
3) Increasing turnover 3years
4) Increasing eps over last 3years
5) I thought the results were good but played down by Sugar as is his way.
6) Interesting Nick knacks with suggestion for boxes of increasing turnover
7) SP Trend line form June /03 until Sept /05 good. Trend line at 103% per annum
8) There has been announcements of further deals for his boxes


But since then had a retracement to about 150 with a kick back up to 193 in February 05 followed by drop to 131 at 10/6/05. Since then there seems to me to be price break out on goodish volume on the 10th /6/05,

I think the trend is reversing but appreciate opinions. I still have reasonable tranche of these and intend holding until annual report 23/9/05

Against it is question whether it shows signs of further retracement, although the SP to-day was up.

Comments welcome on this share and others.

Apparently there will be some new to-morrow or within a few days.

http://www.bioprogress.com/html/news/news.html

Pholden
I would agree with you.

5year graph looks good trend as you say intact.

MACD look good

Trix Looks good (I use a short term, although it is supposed to be long term indicator.)


RSI (15 day) is a touch above 70



Looking back over the volumes for two to three years the volumes increase with the price were a little small.

BUT BUT BUT
Travis Perkins moderates FY expectations as trading remains challenging UPDATEAFX
(Adds further comment from company)LONDON (AFX) - Travis Perkins PLC, the builders' merchant and DIY retailer, said trading is set to remain challenging for the rest of 2005 and it has therefore 'moderated' its expectations for the year.In a trading statement, Travis Perkins said group turnover for the first six months, including the effect of the February acquisition of Wickes, was up by 41 pct, but on a like-for-like basis sales were 0.5 pct lower.'We expect the trading environment for the remainder of 2005 to continue to be challenging,' the group said in a trading statement. 'Whilst we have taken prompt action to reduce costs this will not fully offset the impact of the current trading environment, and our expectations have been moderated accordingly.'But the group said progress on the integration of Wickes is proceeding ahead of schedule.At Wickes, total sales for the 26-week period to June 26 were down by 1.7 pct, and 4.9 pct lower on a like-for-like basis, Travis Perkins said.Home delivered showroom sales, which account for around 16 pct of Wickes total turnover, fell by 8.4 pct like-for-like as consumers reined in their spending.Travis Perkins said although the DIY market is showing signs of recovery, this improvement has been patchy and slower than expected.
However from yesterdays Sunday Times by john Whapples
************
Travis Perkins THE nearer you get to the consumer the tougher business is. That's likely to be the message tomorrow from Travis Perkins, the 2.1 billion builders merchant, when it gives a pre-close trading statement Travis, through its ownership of Wickes, is not immune to the high-street chill. But it is not as exposed as a pure DIY operator like B&Q, and Travis's core heavy- side business, which services the jobbing builder, is holding up well.
Trading in the first half of the year has been tough and if it continues, the group will miss full-year profit forecasts of f260m, but only by a'whisker. Investors will be encouraged by an update on the 135m of savings being made from the Wickes deal. These are running slightly ahead of expectation and other areas to save costs have been identified.
The shares have fallen 10% since February, which is in line with its peers. If interest rates are cut, this will boost the housing and DIY market.-

*************************

I am relatively new to TA (Started with scepticism about three years ago, and Still stumbling but learning). But what I am building into my check list before buying (or selling) on a trend is to check when an announcement is going to be announce (like a trading update) and then if I am in profit consider dumping and re-buying if info is good.
The only problem I can never find the checklist when I feel like buying.

One thing I do pay attention to before buying is the rate of change or speed of overall trend over a short period 2months + and extend it over the year. (percentage change) I suppose it would be fairer to shove the other shares I am looking at on the same chart and compare.

Also I am tending to use log scale prices.

Snip I utilise you method with channels, but I am stupid and only too often over rule my previous decisions. Usually at a price.

Fred

GFRD starting to pick up

Fundy,
The volumes look down for the last couple of days, but if they pick up it would look promising. The percentage rate of change ove the last 6mths is about 12%, but I think that looks like picking up. If the projected PEGs are "correct" it should do.

Fred

Interesting thing about the TPK chart and my commensts was the observation that it may be prudent to await confirmation of the breakout above previous reistance at the 1750 level. I would have used 3% from 1750 and therefore would have waited until the 1800 level was reached before taking a position. The 3% rule would have saved my skin!!

pth

Powered by IST's

This has begun to outperform the Aerospace and defence sector.

This is doing well compared to the All share though not so well compared to the Oil & Gas sector but this looks set to change.

This was one of the shares of the year last year hitting 220 retracing in waves to 75p.
I caught the knife a little to high but with to-days info things look up as does the TA with formation of recent trend reversal.

Volume appears to be going with price rise and momentum and ROC etc, look promising. It has supportat 70p

I think it is worth keeping an eye on and possibly a buy, but how long the uptrend will last I havent a clue.

Alizyme PLC
07 July 2005


For Immediate Release 7 July 2005


ALIZYME REACHES AGREEMENT WITH FDA

FOR RENZAPRIDE PHASE III CLINICAL TRIAL


Cambridge UK, 7 July 2005: Alizyme plc (LSE:AZM) announces that it has reached agreement with the US Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) procedure for the design of a pivotal Phase III clinical trial for renzapride in constipation-predominant irritable bowel syndrome (c-IBS) in the US.

The trial will be a multi-centre, randomised, double-blind, placebo-controlled, parallel group, pivotal, efficacy study. The trial will involve up to 1,700 women with c-IBS being treated over a 12-week period. Patients' response will be determined by each patient, via weekly self-assessments of their IBS symptoms.
The primary endpoint will be to evaluate whether daily doses of renzapride, taken either as 4 mg once daily or 2 mg twice daily, are clinically and statistically significantly more effective than placebo in providing overall symptomatic relief of c-IBS in women between 18 and 65 years of age. Secondary endpoints include adequate relief of abdominal pain/discomfort and of bowel problems.

It is expected that patient recruitment will commence in Q4 2005 and, assuming anticipated recruitment timelines are met, Alizyme would expect results to be available in the first half of 2007.

Commenting, Dr Richard Palmer, Chief Executive Officer, said:

'We are extremely pleased to have reached agreement with the FDA, following extensive discussions, for this pivotal Phase III clinical trial of ren zapride in the US. This is a major achievement for both renzapride and the Company as it takes a second product from our portfolio into Phase III clinical development.'



Previous news



AFX News Feed
Thursday, 30/06/05, 16:24
Alizyme knows no reason for share movement, says finances strong

LONDON (AFX) - Alizyme PLC, the UK-based speciality biopharmaceutical development company, said it has noted the recent movement in its share price, adding it knows no reason for this. The company said following a 30 mln stg fundraising last April, it has sufficient funds to carry forward all its development programmes and for operations into 2008, during which time it expects to have made "significant progress in commercialising its portfolio." "Alizyme anticipates strong news flow later this year generated by progress in its product pipeline," it said. "Alizyme's late stage portfolio of four clinical products continues to progress according to plan," said CEO Dr Richard Palmer. "We are also in our strongest ever financial position and expect to report on significant progress in our product pipeline during 2005."




Comments appreciated.

Was this the news AZM chart was waiting for. Seems to be pivoting with definite uptrend forming.

Alizyme ready to start next trial of diabetic weight loss drugAFX
LONDON (AFX) - Alizyme PLC said it has completed recruiting patients for the second Phase II trial of its treatment for causing weight loss in obese diabetics, cetilistat.Initial results are due around the middle of December.The trial compares three doses of cetilistat with placebo and with orlistat, Roche AG's marketed treatment which brings in annual sales of around 500 mln usd.'The headline results, expected later this year, will mark the completion of Phase II development of cetilistat and confirm its product profile and competitive position in anticipation of its entry into Phase III development in 2006,' chief executive Dr Richard Palmer said in a statement.Alizyme shares close at 92.75 pence yesterday, valuing the group at 165 mln stg.amy.brown@afxnews.comab/bam

this is a speculative punt on a small oil and gas exploration Co. formed out of the old cash shell left over when Gold Mines of Sardinia merged with a canadian Co to form Medoro Resources. Medoro inherited the land in Sardinia, containing inferred millions of ounces of gold, but, for reasons unknown, dropped like a stone. Meanwhile CHP has quadrupled on speculation of exploration in land owned in Paraguay and more recently, it has gone up a gear in anticipation of permits to explore for oil in Columbia, would appear to be a dangerous part of the World! The chart looks good to me but this is a mining exploration Co so I suppose could also drop like a stone with any bad or no news. Interestingly an EGM is planned for 18.7.05, to authorise fundraising by way of share issue, should permits be granted in Colombia.
Apologies now if graph doesn't appear

The charts at first glance look impressive, but volume down to-day. and short MACDs not as good as I would like. Many of indicators seemed positive though. Also with the story you give I think I will sit this one out. To many "ifs" for me.

Interesting pennant formation on recent Proteome Sciences (PRM) chart:

Havent check it out very much but, SP growth about 21% over 3/12 makes it interesting.

Like to see volume a little more established.

Trix looks a bit sad.

I see your pennant formation, but not sure how reliable it is.

Would prefer for myself to see which way the break is. But it should be up.

I have included a few more picrtures.

Havent ckecked the news, dates or Fundies.

To tired at the moment pondering the simplicities if network connections.

Many thanks Fred.

Brief background on news, dates, funds etc for Proteome Sciences:

Enough cash until around Q2 2007 assuming no new revenues, following a Placing earlier this year funded by Fidelity. HOA announced 1st April for significant deal on their TMT (proteomics analysis) technology including upfronts milestones and possibly royalties, deal completion expected soon. Further deals on biomarker licencing expected in remaining part of this year, including stroke diagnosis by blood test (lab screening). Annual results were announced in June, consistent cashburn at around 4m with no plans to significantly increase expenditure. Still a 'blue-sky' company though, with all the inherent risks attached - but one of the safer ones in my view, due to no need for expensive and lengthy drug trials (if the word 'safe' can ever be realistically applied to a biotech investment!)

Thanks I will put it on my Watch and have a look at the weekend.

Must admit I am very heavy into SEO and RTD at the moment. Unless somebody drops the Hbomb to-morrow after a miserabble week or so recovering very nicely.

I have to admit I m beginning to get jumpy about companies not making a profit/

I feel I have supported them for long enough. But I do get hooked on ideas still.

blue mango,

thought you might like to see this from ICV sometime ago:
10 June 2005

PROTEOME SCIENCES (PRM)




In the absence of positive newsflow about licensing agreements, Proteome has had a bumpy ride recently. The shares did enjoy a bounce a couple of months ago on news that the company was moving towards signing a licensing deal for the reagents it has developed to help the diagnosis and treatment of disease. Unfortunately, though, there was no firm update on the deal with these results, although an announcement is expected in the next few weeks.

No longer just a scientific research company, Proteome now has a whole range of products and services for use in diagnosis and treatment of diseases such as cancer, strokes, Alzheimer's and CJD. And, in collaboration with Intronn of the US, Proteome is also developing liver-screening products. This will tap into the huge cholesterol-drugs market - worth $24bn a year in the US alone. Proteome expects a rising tide of milestone and royalty payments this year. Cash resources of more than 7m should help meet annual cash-burn needs, currently running at 3.6m, until income flow picks up.


Subject: Production & sales stats.
Date: Thu 11th Aug 2005 16:47:20
Country: United Kingdom
Industry: Health care
Company: Proteome Sciences PLC


Proteome Sciences says 'satisfactory' progress in Tandem Mass Tags license deal

LONDON (AFX) - Proteome Sciences PLC said the process of concluding a licence agreement for its Tandem Mass Tags is continuing satisfactorily, and that a further announcement will be made when the deal is formally concluded.


The chart is beginning to be promising.

Don't hold it as I have all my pennies in RTD and SEO.

Morning Fred

Not sure where I've been over the summer but I have only just discovered your thread. (Too busy watching the lads getting stuck into the Aussies). As an ex-physicist I like the idea of trying to analyse price movements from graphs and spot trends. Like many folks here I am relatively new to investing (2yr) but have enjoyed some success with long term trends such as TPT. Pity that trend is over. It was much better than putting your money in the bank!
Most of my cash at present is in SEO,NTL and RTD, all of which look as if they might be pushing upwards soon.
Have a little spare cash so will be watching your thread carefully for new investment opportunities.

Keep up the good work

B2B

PS There is an excellent book by Jack D Schwager cvalled Getting started in Technical Analyisis published by John Wiley (approx 13)

B2B,


Like you I have a large holdings in RTD 25%, SEO 20%, and surprisingly BRW 14.6%, BPRG 6.8%, CSN 6.3% and VLK 5.8%, DNX,AZM and a few smaller holdings.

Got out of TPT sometime ago

The charts of the first RTD and SEO to me are less than impressive at the moment, but I think and hope will improve over next 2-6 weeks. I think my holdings of these are based on past record and I hope Fundamentals, we will see. ( I wish I had sold like some cleverer (Bs) a little while ago and then had courage to rebuy on their retracement, but I hope that I have time to live and learn.)

If you are interested in trends have a look at BRW and CSN, DNX, VLK the rate of growths are good and Fundamentals seem OK. But wouldnt buy CSN for a week or two, it seems to be retracing to previous support line. Not sure.

BPRG , AZM, I think have broken out and are in uptrend again.

If you havent got a software package for portfolio management, try a trial period of Sharescope Gold.

Down loads end of the day data, and I think its Fundamentals, Data mining and Charting features are extremely good. I only wish I had started using the Data mining feature 10years ago.

The datamining facility allows you to scan the market for fast growth in SPs over different time scales, pick the capitalization, yields, EPs PEGS etc. ectc.

You can automatically chart your choice superimposed other shares if you wish. The charting tools allow you to measure rate of change of the trends.

It has numerous indicators etc.

Sharescope is very powerful, reasonably priced and enables regular and easy monitoring of holdings.

If you are interested in Trend following and having a look at indicators try
Technical Analysis for Dummies by Barbara Rockefeller. One of the best books I have read on TA. I have read it 3-4 times and found it contains a lot of down to earth information.
Another book is Martin Prings Introduction to TA. ( + CD and book).

Give me a bell if you want more info, but I am off to France for 3weeks after Friday.

BUT DYOH.

By the way a trend was good up to yesterday and no guarantee to the future, as I know only to well. 8-(

Hi Fred

Forgot to mention SHI. Not going to make you a millionaire over night but very good steady growth over the long term. Sorry unable to add charts still learning.

Cheers

B2B